Christopher Fuglesang is Director & 10% Owner at Mirati Therapeutics, Inc. (MRTX). They have made 3 open-market trades across 2 companies since 2017, most recently 2021-04-01.
CIK 0001465835
2 open-market purchases totalling $16.2M since 2017, against 1 sale. Too few scored purchases to measure a record yet.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.